161 related articles for article (PubMed ID: 12732878)
1. 'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning.
Porter DL; Stadtmauer EA; Lazarus HM
Bone Marrow Transplant; 2003 May; 31(9):739-46. PubMed ID: 12732878
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A
Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic transplantation for Hodgkin's lymphoma.
Corradini P; Sarina B; Farina L
Br J Haematol; 2011 Feb; 152(3):261-72. PubMed ID: 21155760
[TBL] [Abstract][Full Text] [Related]
7. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma.
Claviez A; Sureda A; Schmitz N
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S16-24. PubMed ID: 18978738
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease.
Hale GA; Phillips GL
Cancer Treat Rev; 2000 Dec; 26(6):411-27. PubMed ID: 11139372
[TBL] [Abstract][Full Text] [Related]
9. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
[TBL] [Abstract][Full Text] [Related]
10. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
[TBL] [Abstract][Full Text] [Related]
11. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.
Anderlini P; Acholonu SA; Okoroji GJ; Andersson BS; Couriel DR; De Lima MJ; Donato ML; Khouri IF; Giralt SA; Ueno NT; Champlin RE
Bone Marrow Transplant; 2004 Sep; 34(6):511-4. PubMed ID: 15273710
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
Buser AS; Heim D; Bucher C; Tichelli A; Gratwohl A; Passweg JR
Bone Marrow Transplant; 2004 May; 33(10):1011-4. PubMed ID: 15064693
[TBL] [Abstract][Full Text] [Related]
13. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
Corradini P; Dodero A; Zallio F; Caracciolo D; Casini M; Bregni M; Narni F; Patriarca F; Boccadoro M; Benedetti F; Rambaldi A; Gianni AM; Tarella C
J Clin Oncol; 2004 Jun; 22(11):2172-6. PubMed ID: 15169805
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
Nachbaur D; Greinix HT; Koller E; Krieger O; Linkesch W; Kasparu H; Pober M; Hinterberger W; Hausmaninger H; Heistinger M; Ulsperger E; Karlhuber S; Schwinger W; Lindner B
Ann Hematol; 2005 Jul; 84(7):462-73. PubMed ID: 15726362
[TBL] [Abstract][Full Text] [Related]
15. Therapy of relapsed Hodgkin lymphoma.
Cashen AF; Bartlett NL
Blood Rev; 2007 Sep; 21(5):233-43. PubMed ID: 17683834
[TBL] [Abstract][Full Text] [Related]
16. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
Anderlini P; Saliba R; Acholonu S; Okoroji GJ; Donato M; Giralt S; Andersson B; Ueno NT; Khouri I; De Lima M; Hosing C; Cohen A; Ippoliti C; Romaguera J; Rodriguez MA; Pro B; Fayad L; Goy A; Younes A; Champlin RE
Bone Marrow Transplant; 2005 May; 35(10):943-51. PubMed ID: 15806128
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.
Popat U; Hosing C; Saliba RM; Anderlini P; van Besien K; Przepiorka D; Khouri IF; Gajewski J; Claxton D; Giralt S; Rodriguez M; Romaguera J; Hagemeister F; Ha C; Cox J; Cabanillas F; Andersson BS; Champlin RE
Bone Marrow Transplant; 2004 May; 33(10):1015-23. PubMed ID: 15048145
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma.
Seropian S; Bahceci E; Cooper DL
Bone Marrow Transplant; 2003 Oct; 32(8):763-9. PubMed ID: 14520419
[TBL] [Abstract][Full Text] [Related]
20. [Stem cell transplantation in patients with low-grade non-Hodgkin lymphoma].
Mandigers CM; Schattenberg AV; Raemaekers JM
Ned Tijdschr Geneeskd; 2000 Oct; 144(43):2045-8. PubMed ID: 11072506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]